US Patent Issued to GeneCraft on Sept. 16 for "Pharmaceutical composition comprising RUNX3 protein and CDK4 inhibitor or mTOR inhibitor cotreatment for prevention or treatment of cancer" (South Korean Inventors)

ALEXANDRIA, Va., Sept. 17 -- United States Patent no. 12,414,980, issued on Sept. 16, was assigned to GeneCraft Inc. (Cheongju-si, South Korea).

"Pharmaceutical composition comprising RUNX3 protein and CDK4 inhibitor or mTOR inhibitor cotreatment for prevention or treatment of cancer" was invented by Suk Chul Bae (Cheongju-si, South Korea), Jung Won Lee (Daejeon, South Korea) and You Soub Lee (Cheongju-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, comprising a Runx3 (Runt-related transcription factor 3) protein, a polynucleotide encoding thereof, a vector carrying the polynucleotide or a viru...